Ovarian Cancer | Tumor

CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.

Fosbretabulin and Avastin Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer

April 1st 2015, 1:12am

Article

Pretreated patients with recurrent ovarian cancer had a 2.5-month progression-free survival benefit when receiving fosbretabulin plus Avastin compared with Avastin alone; however, hypertension rates doubled.

Avastin Regimen Shows Survival Trend in Phase 3 Ovarian Cancer Trial

March 30th 2015, 10:08pm

Article

Treatment with Avastin plus chemotherapy resulted in an improvement in overall survival of nearly five months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015, 8:25pm

Article

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage 3/4 ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not, according to an open-label phase 2 trial.

The Advantages of Intraperitoneal Chemotherapy for Ovarian Cancer

March 26th 2015, 8:32pm

Article

Oncologist Don Dizon explains the advantages of intraperitoneal therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment.

NCCN Updates Ovarian Cancer Clinical Practice Guidelines

March 25th 2015, 5:35pm

Article

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of Avastin and Lynparza, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines in its 20th annual edition.

Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers

March 5th 2015, 1:17am

Article

When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.

Getting a Second Opinion

February 16th 2015, 11:28pm

Article

A second opinion can provide answers, ideas and perspective about whether a patient is on the right treatment path.

Role of PARP Inhibitors in Ovarian Cancer Continues to Evolve

February 6th 2015, 11:05pm

Article

On the evolving role of PARP inhibitors in the treatment of ovarian cancer, Donna McNamara, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC), discusses the impact of these studies and the outlook going forward.

The Thing About Risk

January 23rd 2015, 3:09am

Article

There are some things known to increase the risk of gynecologic cancers. Bottom line, being a woman puts you at risk.

PARP Inhibitor Approved for BRCA-Positive Advanced Ovarian Cancer

December 20th 2014, 3:17am

Article

The Food and Drug Administration approves Lynparza (olaparib) for the treatment of women with BRCA-positive advanced ovarian cancer.